Term
| 3 of the following 5 criteria are required for dx of metabolic syndrome: |
|
Definition
- Waist circumference greater than 40 in in men and 35 in in women - Triglycerides greater than or equal to 150 - Low HDL, less than 40 for men, less than 50 for women - Raised blood pressure ,greater than or equal to 130/85 - Fasting blood glucose greater than or equal to 110 |
|
|
Term
| LDL enters endothelium and intima> oxidized, macrophages and smooth muscle join> foam cells and fatty plaques> grow and grow and grow> plaque becomes unstable and fractures> clot forms> heart attack |
|
Definition
|
|
Term
| Endothelial dysfunction: ability for LDL to pass through endothelium as well and stay and be oxidized, affected by bp and high cholesterol, know this definition |
|
Definition
|
|
Term
| Most imortant factor influencing endothelial dysfunction and atherosclerotic plaque formation is __. |
|
Definition
|
|
Term
| complications of dislipidema: |
|
Definition
Cardiovascular Disease
Obesity
HTN
PVD
Cancer
Combined with DM - Increased risk of CHD
Combined with HTN - Increased risk of CHD/CVA |
|
|
Term
| Risk factors for hyperlipidemia: |
|
Definition
High Fat/High Cholesterol Diet
Obesity
Family History/Genetic BCP use
Smoking
Diabetes and Insulin Resistance
Hypertension
Medications Beta blockers, diuretics, anabolic and corticosteroids, estrogens and progestins, protease inhibitors may elevate lipid levels |
|
|
Term
| Medications that my cause/contribute to hyperlipidemia: |
|
Definition
- beta blockers - diuretics - corticosteroids - bcps - protease inhibitors |
|
|
Term
| 75-80% of diabetic pts have visceral adiposity. |
|
Definition
|
|
Term
Causes of Hyperlipidemia Primary Familial Genetic Familial hypercholesterolemia Familial hyperchylomicronemia
Secondary (most common) Often a combination of primary and secondary Obesity Diabetes Thyroid Ds. Sedentary Lifestyle Medications Liver and Renal Disease Cushing's Disease |
|
Definition
|
|
Term
Types of Lipids Cholesterol Role in cell wall structure, bile and hormone production Most associated with atherogenesis and CV disease Produced in the body in amounts that do not require exogenous sources
Triglycerides Primary lipid in the body Primary storage form of lipid Highest concentration in LDL’s/VLDL Elevated levels associated with increased CV risk but association not well understood |
|
Definition
| Current theory is that high trigs mask high particle numbers of LDLs> increased cardiovascular diseae. |
|
|
Term
Lipoproteins Responsible for lipid transport As well as composed of lipids but proteins called apoproteins Classified by density Chylomicrons Least dense. Formed to carry fats from the gut. HDL Most dense and smallest HDL-C is the most important HDL for CV health LDL VLDL --> least dense and largest LDL. Composed mainly of triglycerides IDL LDL --> smaller and most cholesterol dense --> most associated with atherogenesis (LDL-c) Lipoprotein (a) An LDL like lipoprotein particle also involved in lipid transport. Also contains Apolipoprotein B. |
|
Definition
|
|
Term
| The __ and __ the LDL, the more atherogenic it is. ___ __ is the smallest LDL, so it is the most atherogenics. |
|
Definition
- smaller and denser - Lipoprotein A |
|
|
Term
| Lipoprotein A has ___ __, which is the driver of all bad cholesterols. |
|
Definition
|
|
Term
Apolipoproteins Apolipoproteins are proteins that bind to lipids. They form lipoproteins which transport lipids such as LDL through the bloodstream. These proteins enhance and are involved in controlling lipid transport.
Apolipoproteins also serve as enzyme co-factors, receptor ligands, and lipid transfer carriers that regulate the metabolism of lipoproteins and their uptake in tissues.
Six Classes of Apolipoproteins A, B, C, D, E, H
Apolipoprotein B is found in all lipoproteins especially chylomicrons, VLDL, IDL, and LDL. Apo B-100 specific for all LDL particles |
|
Definition
|
|
Term
| ___ is a key tool to understanding lipid risks in pts. |
|
Definition
|
|
Term
| __ _ is closely associated with HDL. |
|
Definition
|
|
Term
|
Definition
- TC (total cholesterol) - HDL - LDL - TGY - Total cholesterol/HDL ratio - Non-HDL cholesterol - Apoprotein A/B - Lipoprotein A - Lipoprotein lipase - Fractionated LDL |
|
|
Term
| The non-HDL is now becoming commonly placed in lipid panels.Determined by subtracting HDL from the TC= non-HDL number. Tends to give better understanding of atherogenic burden of LDL in body. Primarily applied with trigs are above 200 |
|
Definition
|
|
Term
| More precise measure of LDL? |
|
Definition
|
|
Term
Total Cholesterol High > 240 mg/dl High Normal 200-239 mg/dl Normal < 200 mg/dl HDL Normal > 40 mg/dl Low < 40 mg/dl LDL High >160 mg/dl Borderline High 130 - 159 mg/dl Normal <130 mg/dl Optimal <100 mg/dl (< 70 high risk) Triglycerides Normal < 150mg/dl High Normal 150 – 199mg/dl High 200 – 499mg/dl Very High > 500mg/dl Non-HDL Cholesterol Normal < 160mg/dl Optimal < 130 mg/dl High Risk < 100 mg/dl Total Cholesterol/HDL Ratio Normal < 5:1 Optimal < 3.5:1 Apolipoprotein B Normal <100mg/dl High Risk <80-90mg/dl |
|
Definition
|
|
Term
| normal total cholesterol: |
|
Definition
|
|
Term
| high normal total cholesterol: |
|
Definition
|
|
Term
|
Definition
| greater than or equal to 240 mg/dl |
|
|
Term
|
Definition
| greater than or equal to 40 |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| optimal LDL for high risk pts? |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| greater than or equal to 160 mg/dl |
|
|
Term
|
Definition
|
|
Term
| High normal triglycerides: |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| normal Non-HDL cholesterol: |
|
Definition
|
|
Term
| Optimal non-HDL cholesterol? |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Normal total cholesterol: HDL ratio: |
|
Definition
|
|
Term
| Optimal total cholesterol: HDL ratio: |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Optimal apolipoprotein B: |
|
Definition
|
|
Term
| bottom line essential targets: |
|
Definition
TC < 200 mg/dl
HDL Men > 45 mg/dl Women > 50 mg/dl
LDL Everyone < 160 mg/dl 2+ Risk/<20% < 130 mg/dl CHD/CHD Equivalent < 100 mg/dl CHD/CHD Equivalent (High Risk) < 70 mg/dl
Triglycerides Everyone < 200 mg/dl CM Risk Factors < 150 mg/dl
Non-HDL (Primarily those with hypertriglyceride) Everyone < 130 mg/dl CM Risk Factors < 90 mg/dl
TC/HDL Ratio Everyone < 4:1 |
|
|
Term
| Age 20 or older pts, should have lipid panel at least every 5 years. |
|
Definition
|
|
Term
The U.S. Preventive Services Task Force (USPSTF) recommends that:
>All men aged 35 and older and all women aged 45 and older should be screened routinely for lipid disorders. (“A” Recommendation)
>Younger adults—men aged 20-35 and women aged 20-45—should be screened if they have other risk factors for heart disease. These risk factors include tobacco use, diabetes, a family history of heart disease, high cholesterol, or high blood pressure. (“B” Recommendation)
> Recommended screening tools: HDL and Total Cholesterol. There is insufficient evidence to recommend for or against measuring triglycerides. |
|
Definition
|
|
Term
| Once 35 or 40, should routinely screen lipids (every year). |
|
Definition
|
|
Term
| LDL lowering is important for all patients, but especially important for Diabetics. Primary target always LDL. Secondary target HDL. |
|
Definition
|
|
Term
ATP III Guidelines (Assessment and Therapeutic Approach) Primary Target Lower LDL
Secondary Target HDL/TGY
If elevated TGY the Secondary Target is Non-HDL then HDL/TGY
If Metabolic Syndrome/Diabetes/CV Ds the secondary target is Non-HDL, HDL, TGY, ApoB. |
|
Definition
|
|
Term
| with 0-1 risk factor for CHD, LDL goal should be less than __. Drug therapy should be initiated when greater than or equal to __. |
|
Definition
|
|
Term
| With 2+ risk factors for CHD or 10 year risk of 20%, LDL goal should be less than __. If 10 year risk is between 10 and 20% initiate drug tmt at __. If 10 year risk is less than 10% initiate drug therapy at __. |
|
Definition
|
|
Term
| With CHD or CHD risk equivalents, the LDL goal should be less than __ and drug tmt should begin at __. |
|
Definition
|
|
Term
| Atherogenic dislipidemia primary, secondary, and tertiary goals: |
|
Definition
- target elevated LDL - target elevated non-HDL - reduce Apo-B, increase HDL |
|
|
Term
| Non–HDL-C is a stronger predictor of CHD risk than LDL-C |
|
Definition
|
|
Term
TLM Diet Saturated fat < 7 % of calories, No Trans Fats Increase fiber (Oatmeal) Fruits, vegetables, nuts, legumes Fish, poultry Less red meat, less fried/processed foods Add breakfast Small portions
Weight management Target BMI < 30
Increased physical activity (Daily aerobic activity at a minimum/at least 150 minutes weekly)
Wellness/Disease Screening |
|
Definition
|
|
Term
TLM Diet Saturated fat < 7 % of calories, No Trans Fats Increase fiber (Oatmeal) Fruits, vegetables, nuts, legumes Fish, poultry Less red meat, less fried/processed foods Add breakfast Small portions
Weight management Target BMI < 30
Increased physical activity (Daily aerobic activity at a minimum/at least 150 minutes weekly)
Wellness/Disease Screening |
|
Definition
|
|
Term
Always consider drug simultaneously with TLC for CHD and CHD equivalents
In general, consider adding drug to TLM after 3 months for other risk categories. Individualize.
There are now lipid lowering drug combinations |
|
Definition
|
|
Term
| Initiate LDL lowering drug (statin), see pt back in __ __. If not at goal then, increase dose for another __ _. If still not at goal, treat other __ __ __. Then still not at goal, monitor adherence. |
|
Definition
- 6 weeks - 6 weeks - other lipid risk factor |
|
|
Term
If LDL over 200, TLC is not going to be enough> start on medication initially. Statins are best lipid lowering drugs (LDL). Statins are very effective at getting LDL down.
Simvastatin is strongest, then Atorvastatin. |
|
Definition
|
|
Term
| __ __ __ __ are the DOC of choice for elevated LDL and Total Cholesterol. These are the most commonly prescribed meds for dyslipidemia. The decrease LDL by __%, increase HDL by __, and decrease TGY by ___. |
|
Definition
- HMG-CoA reductase inhibitors - 18-55% - 5-15% - 7-30%
Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin, Pitavastatin |
|
|
Term
| Side effects of HMG-CoA reductase Inhibitors: |
|
Definition
- myopathy/rhabdomyolysis (CPK monitoring) - Increased liver enzymes (AST/ALT monitoring) |
|
|
Term
| 2 HMG-CoA reductase inhibitors that help increase HDL and decrease TGY: |
|
Definition
|
|
Term
| Contraindications to HMG-CoA Reductase Inhibitors: |
|
Definition
ABSOLUTE: active liver diseaes Relative: use of certain drugs like (CMAC) - cyclosporine - macrolide - anti-fungal - CYP-450 inhibitors - fibrates and niacin with caution |
|
|
Term
| EVIDENCE THAT LOW VITAMIN D LEVELS ATTRIBUTE TO STATIN RESISTANCE> SO CHECK VITAMIN D, so if increase vitamin D, then maybe not statin resistant. |
|
Definition
|
|
Term
|
Definition
- flushing - hyperglycemia - hyperuricemia (gout) - upper GI distress - hepatotoxicity |
|
|
Term
|
Definition
Absolute: chronic liver disease, severe gout Relative: Diabetes, Hyperuricemia, PUD |
|
|
Term
| Niacin clinical trial results: |
|
Definition
| reduced major coronary events and possibly total mortality |
|
|
Term
| Niacin is mainly used to boost HDL, but it also decreases LDL and TGYs a little bit. |
|
Definition
|
|
Term
| Bile acid sequestrants decrease __ and increase __, but have no effect on __. |
|
Definition
|
|
Term
| Fibrates decrease __ and __, while increasing __. |
|
Definition
|
|
Term
| Fibrates mainly used for high __. |
|
Definition
|
|
Term
| Bile acid sequestrant side effects: |
|
Definition
- GI distress - constipation - decreased absorption of other drugs |
|
|
Term
| If pt has high TGY, do NOT use __ __ __, these make high TGY worse. |
|
Definition
|
|
Term
| Bile acid sequestrant CI; |
|
Definition
Absolute: dysbetalipoproteinemia, TG> 400 Relative: TG> 200 |
|
|
Term
| Bile acid sequestrants clinical trial results: |
|
Definition
- reduced major coronary events - reduced CAD deaths |
|
|
Term
|
Definition
- dyspepsia - gall stones - myopathy - unexplained non-CAD death |
|
|
Term
|
Definition
- dyspepsia - gall stones - myopathy - unexplained non-CAD death |
|
|
Term
|
Definition
- severe renal disease - severe hepatic disease |
|
|
Term
| FIBRATES CLAIM TO FAME IS TRIG LOWERING. ALSO MODESTLY RAISE HDL. |
|
Definition
|
|
Term
| Bile acid sequestrants aka __. Name the drugs in this class. |
|
Definition
- Resins - Cholestyramine - Colestipol - Colesevelam |
|
|
Term
| Only lipid lowering class of drugs approved during pregnancy: |
|
Definition
|
|
Term
| class of lipid lowering drugs that may actually increase TGY? |
|
Definition
|
|
Term
|
Definition
- increase HDL and decrease TGY
(modest effect on LDL) |
|
|
Term
| __ taken 30 min before Niacin can decrease flushing. Or can tell pt to eat a __ __ __ like applesauce with the Niacin to decrease flushing. |
|
Definition
- Aspirin - pectin-containing food |
|
|
Term
| __ __ are the __ for lowering TGY (especially when over 500), or this class of drugs can also be used with statins. |
|
Definition
|
|
Term
| 3 Fibrate/Fibric Acid drugs; |
|
Definition
- Gemfibrozil - Fenofibrate - Clofibrate |
|
|
Term
|
Definition
Lipid Effects: Decrease LDL 5-20% (may increase in pts with high TG) Increase HDL 10-20% Decrease TG 20-50% |
|
|
Term
| Cholesterol Absorption Inhibitors like __ are usually used in combo with a statino reach LDL goal, but can be used alone for mild LDL goals. |
|
Definition
|
|
Term
| Cholesterol Absorption Inhibitor actions: |
|
Definition
- decrease LDL - decrease ApoB - decrease total cholesterol |
|
|
Term
| Side effects of cholesterol aborption inhibitors (Ezetimibe): |
|
Definition
- Arthralgias - Back pain - Abdominal pain - Diarrhea - Cough |
|
|
Term
| Precautions of using cholesterol absorption inhibitors (Ezetimibe) |
|
Definition
- elevated liver enzymes, especially when used with fibrate - caution use with cyclosporine |
|
|
Term
| contraindications to cholesterol absorption inhibitors (Ezetimibe) |
|
Definition
|
|
Term
| Lovaza is __ __ __ __ or __ __. |
|
Definition
| omega 3 fatty acid or fish oil |
|
|
Term
| Fish oil (lovaza) is used primarily to lower __, it may also __ __. |
|
Definition
- lower triglycerides - increase HDL |
|
|
Term
| Lovaza (fish oil) side effects: |
|
Definition
- eructation - infection - flu like syndrome - dyspepsia - taste changes - back pain |
|
|
Term
| fish oil can interact with many meds. |
|
Definition
|
|
Term
| 3 options for treating non-HDL: |
|
Definition
fibrates niacin combo therapy |
|
|
Term
| If TGY are greater than or equal to 500 mg/dl, first lower the __ to prevent __. |
|
Definition
|
|
Term
| TGY greater than or equal to 500 managment: |
|
Definition
First lower TG to prevent pancreatitis Very low-fat diet ( 15% calories from fat) Weight management and exercise Fibrate, nicotinic acid, Omega 3FA When TG < 500, turn to LDL lowering tx |
|
|
Term
|
Definition
First reach LDL Goal Intensify weight management and increase physical activity If TG 200-499 mg/dl, achieve non-HDL goal If TG < 200 mg/dl (isolated low HDL) in CHD or equivalent, consider fibrate and/or nicotinic acid ETOH and Omega-3 FA’s elevate HDL |
|
|
Term
| __ are good at lowering CRP and other inflammatory agents. |
|
Definition
|
|
Term
in order from weakest to strongest of statins:
Simvastatin..Atorvastain...Rosuvastatin
(Rosuvastatin is the strongest) |
|
Definition
|
|